Comorbidities and safety in a cohort of patients with progressive non-active form of multiple sclerosis treated with MD1003
Latest Information Update: 22 Jan 2020
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2018 New trial record
- 12 Oct 2018 Results assessing the effectiveness of a 12-month treatment with MD1003 on dexterity, cognition, and quality of life (QOL) measures presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results identifying side effects and comorbidities in a cohort of patients with progressive non-active form of MS presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis